Table 3.
Seropositivity Rates According to Treatment Status
| Author | CLL N | Response (n Evaluable) | |||
|---|---|---|---|---|---|
| Treatment-naive | Active Treatment | Prior Treatment | In Remission | ||
| Second dose | |||||
| Sun et al (2021)35 | 58 | 71% (21) | 50% (34) | 100% (3) | NA |
| Dong et al (2021)30 | 23 | 81.3% (16) | 28.6% (7) | NA | NA |
| Shen et al (2021)27 | 160 | 63.4% (82) | 21.9% (32) | NA | 67.5% (40)a |
| Molica et al (2021)33 | 70 | 87% (23) | 41.7% (36) | NA | 87.5% (8)a |
| Parry et al (2022)36 | 500 | 78% (284) | 43% (200) [on/prior] | 73% (11)b | 71% (75) |
| Bagacean et al (2022)32 | 506 | 72% (210) | 22% (166) | 60% (130) | NA |
| Benjamini et al (2022)37 | 373 | 61% (158) | 14% (113)c | 42% (55)d | NA |
| Herishanu et al (2021)40 | 167 | 55.2% (58) | 16% (75) | 64.7% (34) | 79.2% (24) |
| Roeker et al (2021)38 | 44 | 94% (18) | NA | 23% (26) | NA |
| Tadmor et al (2021)39 | 84 | 76.2% (16) | 28.6% (6) | 61.9% (26) | 27.2% (22) |
| Bergman et al (2021)34 | 79 | 84.6% (26) | NA | NAe | NA |
| Ujjani et al (2022)23 | 37 | 50% (14) | NA | NA | NA |
| Haydu et al (2022)41 | 36 | 72% (25) | 33% (6) | 0% (5) | NA |
| Molica et al (2022)31 | 2082 | 73% (533) | NA | NA | NA |
| Haggenburg et al (2022)45 | 94 | 70% (56) | NA | NA | NA |
| Third dose (booster results) | |||||
| Herishanu et al (2022)42 | 172 | 40% (40) | 12% (100) | 40.6% (32) | 41.7% (24) |
| Del Poeta et al (2021)44 | 46 | 88.2% (17)f | 34.5% (29) | NA | NA |
aComplete or partial remission.
bPrior targeted therapy.
cTargeted therapy.
dPrior targeted therapy.
ePrior ibrutinib: 9 (55.6%); prior anti-CD20 (median 13 mo): 18 (88.9%). fIncludes prior treatment.
CLL = chronic lymphocytic leukemia; n = number of patients; NA = not available.